FDA Approvals, Diversified Product Pipeline, Produce Sales Growth, and Positive Study Outcomes - Research Report on Boston Scientific, Zimmer, St. Jude, ResMed, and GenMark Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, June 21, 2013 NEW YORK, June 21, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Boston Scientific Corporation (NYSE: BSX), Zimmer Holdings, Inc. (NYSE: ZMH), St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), and GenMark Diagnostics, Inc. (NASDAQ: GNMK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Boston Scientific CorporationResearch Report On June 18, 2013, Boston Scientific Corporation's (Boston Scientific) Vercise Deep Brain Stimulation (DBS) System demonstrated significant improvement in motor function for patients with Parkinson's disease. This is according to interim data from the VANTAGE DBS study. Data from the six month follow-up of up to 40 participants enrolled in the VANTAGE trial were presented at the annual International Congress of Parkinson's Disease and Movement Disorders, held at Sydney. Preliminary analysis of the VANTAGE study displays approximately 60% mean improvement in motor function at six months post implant, as assessed by UPDRS III when compared to baseline. "The VANTAGE study is a key facet of our DBS program and emphasizes our commitment to advancing therapy through clinical research with the Vercise DBS System," said Maulik Nanavaty, President of the Boston Scientific Neuromodulation Division. "The significance of the reduction in motor scores is a testament to the capabilities of the Vercise System. We continuously strive to develop innovative technologies that improve patient outcomes." The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/5649_BSX] -- Zimmer Holdings, Inc.Research Report On June 4, 2013, Zimmer Holdings, Inc. (Zimmer) announced that it has completed the acquisition of Germany-based NORMED Medizin-Technik GmbH. The acquired entity is a provider of technologies for the foot and ankle, hand and wrist reconstruction and trauma markets. NORMED also develops a broad range of specialized plates, screws and instruments. The Company stated that the acquisition of NORMED will strengthen Zimmer's Extremities and Trauma product portfolios and new product development capabilities in the fast growing foot and ankle as well as hand and wrist segments. The Full Research Report on Zimmer Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/9cbd_ZMH] -- St. Jude Medical Inc.Research Report On June 11, 2013, St. Jude Medical, Inc. (St. Jude) announced that the US Food and Drug Administration (FDA) has approved its next-generation Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). These new devices are designed with advanced technologies to provide preventative and adaptive capabilities to address potential failures by lowering the risk of lead abrasion, and to help overcome the inability to deliver high-voltage therapy when needed. "St. Jude Medical strives to deliver the highest levels of patient safety. The new Ellipse ICD and SJM Assura family of devices support those efforts by providing added features that ensure effective therapy delivery," said Eric S. Fain, M.D., President of the St. Jude Medical Implantable Electronic Systems Division. "We are pleased that the FDA approved these devices, allowing us to bring important safety and system reliability enhancements to patients." The Full Research Report on St. Jude Medical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/bf35_STJ] -- ResMed Inc.Research Report On June 5, 2013, ResMed Inc. (ResMed) reported that it has filed a lawsuit in U.S. Federal Court, Southern District of California to stop infringement of ResMed patents. The Company filed the action against the Chinese medical device manufacturer, BMC Medical Co., Ltd. and its U.S. sales subsidiary, 3B Products, LLC asserting patent infringement by its RESmart CPAP, RESmart Auto CPAP devices; and the Willows nasal pillows patient interface and the iVolve nasal mask. "ResMed has built its unique market differentiation by investing in superior technology and medical science-driven innovation for sleep-disordered breathing therapy," said David Pendarvis, ResMed Global General Counsel and Chief Administrative Officer. "We will continue to defend our proprietary technology by enforcing our patents." The Full Research Report on ResMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/ba41_RMD] -- GenMark Diagnostics, Inc.Research Report On June 17, 2013, GenMark Diagnostics, Inc. (GenMark) updated its annual revenue guidance for FY 2013 (period ending December 31, 2013). The Company stated that the guidance update resulted from the additional uncertainties relating to the future revenue contribution from its largest customer, together with persisting reimbursement and other challenges affecting the emerging pharmacogenomics market sector,. The Company now anticipates annual revenue of approximately $30 million, down compared to its original estimate of approximately $35 million. Hany Massarany, GenMark's President and Chief Executive Officer, said, "As previously communicated, we remained prudently cautious regarding the future revenue contribution from the pharmacogenomics sector, including our single largest customer. In light of the recent developments which introduced additional uncertainty regarding this customer, we have taken a more conservative outlook and reduced our revenue expectations for the remainder of the year." The Full Research Report on GenMark Diagnostics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/ab23_GNMK] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
FDA Approvals, Diversified Product Pipeline, Produce Sales Growth, and Positive Study Outcomes - Research Report on Boston
Press spacebar to pause and continue. Press esc to stop.